(thirdQuint)NASVAC Phase-III Trial in Chronic Hepatitis B (CHB) Patients.

 To collect and assess data on the therapeutic potential of the NASVAC in CHB patients regarding: Reduction of the serum HBV DNA levels.

 Reduction in the levels of alanine aminotransferase (ALT) Clearance of hepatitis B e antigen (HBeAg) Negativation or lowering of HBsAg Anti-HBsAg/anti-HBeAg seroconversion An additional objective of this study is to reconfirm the safety of NASVAC in CHB patients that has previously been shown by us in Phase I-II clinical trial in CHB patients.

.

 NASVAC Phase-III Trial in Chronic Hepatitis B (CHB) Patients@highlight

The general objective of the present clinical trial is to compare the therapeutic efficacy of a combination therapeutic vaccine containing hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg) [later called NASVAC] with a commonly used antiviral drug, pegylated interferon in patients with chronic hepatitis B (CHB).

